Oxygenta Pharmaceutical Ltd vs Cipla Ltd

A side-by-side comparison of Oxygenta Pharmaceutical Ltd (524636) and Cipla Ltd (CIPLA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Cipla Ltd leads 524636 vs CIPLA on 8 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
30.68
-4.18
P/B ratio
3.42
0.00%
Dividend yield
0.89%
₹-2.62
EPS
₹48.02

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

38.69%
Return on equity
11.60%
-25.00%
Return on capital
15.00%
-9.00%
EBITDA margin
21.00%
-9.17%
Net margin
13.71%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

53.89%
Revenue CAGR (3Y)
7.37%
Profit CAGR (3Y)
10.88%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹185 Cr
Market cap
₹1.19L Cr
₹109 Cr
Revenue
₹28,163 Cr
₹-10 Cr
Net profit
₹3,862 Cr
0.00
Debt / equity
0.00
Oxygenta Pharmaceutical Ltd
  • + ["Company's median sales growth is 22.1% of last 10 years"]
  • ["Company has low interest coverage ratio."]
Cipla Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.26%"]
Oxygenta Pharmaceutical Ltd full analysis Cipla Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

524636 vs Cipla Ltd: Share Price, Valuation & Which to Buy | DocStoX